Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review

References

• ColomboNPeirettiMParmaGNewly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v23v3020555088
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkEpithelial Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer) Version 32012Fort Washington (PA)NCCN2012
   Google Scholar
• National Cancer InstitutePrevious version: SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)2012 Available from: http://seer.cancer.gov/csr/1975_2009_pops09Accessed July 23, 2015
   Google Scholar
• LarkinJMKayeSBEpothilones in the treatment of cancerExpert Opin Investig Drugs2006156691702
   PubMed Web of Science ®Google Scholar
• HeLOrrGAHorwitzSBNovel molecules that interact with microtubules and have functional activity similar to TaxolDrug Discov Today20016221153116411700217
   PubMed Web of Science ®Google Scholar
• KowalskiRJGiannakakouPHamelEActivities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol)J Biol Chem19972724253425418999970
   PubMed Web of Science ®Google Scholar
• MozzettiSFerliniCConcolinoPClass III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patientsClin Cancer Res200511129830515671559
   PubMed Web of Science ®Google Scholar
• FumoleauPCoudertBIsambertNFerrantENovel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analoguesAnn Oncol200718Suppl 5v9v1517656562
   PubMed Web of Science ®Google Scholar
• AltmannKHWartmannMO’ReillyTEpothilones and related structures – a new class of microtubule inhibitors with potent in vivo antitumor activityBiochim Biophys Acta200014703M79M9110799747
   PubMed Web of Science ®Google Scholar
• WatkinsEBChittiboyinaAGJungJCAveryMAThe epothilones and related analogues – a review of their syntheses and anti-cancer activitiesCurr Pharm Des200511131615165315892666
   PubMed Web of Science ®Google Scholar
• NicolaouKCWinssingerNPastorJSynthesis of epothilones A and B in solid and solution phaseNature199738766302682729153390
   PubMed Web of Science ®Google Scholar
• HoffmannJVitaleIBuchmannBImproved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopiloneCancer Res200868135301530818593931
   PubMed Web of Science ®Google Scholar
• LeeFYBorzilleriRFairchildCRBMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacyClin Cancer Res2001751429143711350914
   PubMed Web of Science ®Google Scholar
• LiberatiAAltmanDGTetzlaffJThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJ Clin Epidemiol20096210e1e3419631507
   PubMed Web of Science ®Google Scholar
• ColomboNKutarskaEDimopoulosMRandomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerJ Clin Oncol201230313841384722987083
   PubMed Web of Science ®Google Scholar
• McMeekinSPatelRVerschraegenCPhase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancerBr J Cancer20121061707622108514
   PubMed Web of Science ®Google Scholar
• TsimberidouAMLewisNReidTPharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancerCancer Chemother Pharmacol20116861507151621499896
   PubMed Web of Science ®Google Scholar
• RustinGReedNJaysonGCA phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancerAnn Oncol201122112411241621372124
   PubMed Web of Science ®Google Scholar
• ChuangEWienerNChristosPPhase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovaryAnn Oncol201021102075208020357034
   PubMed Web of Science ®Google Scholar
• De GeestKBlessingJAMorrisRTPhase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group studyJ Clin Oncol201028114915319917861
   PubMed Web of Science ®Google Scholar
• Ten Bokkel HuininkWWSufliarskyJSmitWMSafety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation studyJ Clin Oncol200927193097310319451434
   PubMed Web of Science ®Google Scholar
• ForsterMKayeSOzaAA phase IB and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancerClin Cancer Res200713144178418417634546
   PubMed Web of Science ®Google Scholar
• HensleyMLDizonDDerosaFA phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsInvest New Drugs200725433534117364235
   PubMed Web of Science ®Google Scholar
• RubinEHRothermelJTesfayeFPhase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumorsJ Clin Oncol200523369120912916301595
   PubMed Web of Science ®Google Scholar
• ZhuangSHAgrawalMEdgerlyMA phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysCancer200510391932193815800893
   PubMed Web of Science ®Google Scholar
• ManiSMcDaidHHamiltonAPhase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsClin Cancer Res20041041289129814977827
   PubMed Web of Science ®Google Scholar
• AbrahamJAgrawalMBakkeSPhase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJ Clin Oncol20032191866187312721265
   PubMed Web of Science ®Google Scholar
• SchmidPKiewePPossingerKPhase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumorsAnn Oncol201021363363919880436
   PubMed Web of Science ®Google Scholar
• ArnoldDVoigtWKiewePWeekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trialBr J Cancer200910181241124719773753
   PubMed Web of Science ®Google Scholar
• AghajanianCBurrisHA3rdJonesSPhase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasJ Clin Oncol20072591082108817261851
   PubMed Web of Science ®Google Scholar
• AwadaAPiccartMJJonesSFPhase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyCancer Chemother Pharmacol200963341742518446338
   PubMed Web of Science ®Google Scholar
• ChenTMolinaAMooreSEpothilone B analog (BMS-247550) at the recommended phase II dose in patients with gynecologic and breast cancersJ Clin Oncol200422155 Suppl2115
   Google Scholar
• SpriggsDRDupontJPezzulliSKOS-862 (epothilone D): phase 1 dose escalating and pharmacokinetic (PK) study in patients with advanced malignanciesProc Am Soc Clin Oncol200322894
   Google Scholar
• SmitWMSufliarskyJWernerTLA phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancerJ Clin Oncol2009271535563
   Google Scholar
• CalvertPMO’NeillVTwelvesCA phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumorsProc Am Soc Clin Oncol200120429
   Google Scholar
• HaoDHammondLAdeBonoJSContinuous weekly administration of the epothilone-B derivative, BMS247,550 (NSC710428): a phase I and pharmacokinetic (PK) studyProc Am Soc Clin Oncol200221411
   Google Scholar
• PiroLDRosenLSParsonMKOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignanciesProc Am Soc Clin Oncol200322539
   Google Scholar
• DicksonNPeckRWuCBurrisHIxabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trialJ Clin Oncol20062418 Suppl2040
   Google Scholar
• Villalona-CaleroMGoelSSchaafLFirst-in-human phase I trial of a novel epothilone, KOS-1584J Clin Oncol20062418 Suppl2003
   Web of Science ®Google Scholar
• MekhailTChungCHoldenSPhase I trial of novel epothilone B analog BMS-310705 IV q 21 daysProc Am Soc Clin Oncol200322515
   Google Scholar
• SessaCPerottiAMalossiAPhase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancerProc Am Soc Clin Oncol200322519
   Google Scholar
• WozniakKMNomotoKLapidusRGComparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in miceCancer Res201171113952396221498637
   PubMed Web of Science ®Google Scholar
• O’ReillyTMcSheehyPMWengerFPatupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivoProstate200565323124015948135
   PubMed Web of Science ®Google Scholar